Based on data for ritonavir and other protease inhibitors, plasma concentrations of PDE5 inhibitors (e. g. sildenafil and vardenafil) are expected to substantially increase when co-administered with Telzir with ritonavir and may result in an increase in PDE5 inhibitor associated adverse reactions, including hypotension, visual changes and priapism.
Dette kan resultere i en stigning i PDE5- hæmmer associerede bivirkninger, herunder hypotension, visuelle ændringer og priapismus.